203 related articles for article (PubMed ID: 31678370)
41. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
Lally J; Boasman K; Brown L; Martinelli V; Cappuccio I; Sovani V; Marinaccio C; Crispino JD; Graham C; Rinaldi C
J Thromb Haemost; 2019 Jun; 17(6):896-900. PubMed ID: 30889303
[TBL] [Abstract][Full Text] [Related]
42. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
43. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
[TBL] [Abstract][Full Text] [Related]
44. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
[TBL] [Abstract][Full Text] [Related]
45. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
Skov V; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC; Larsen TS
Exp Hematol; 2012 Sep; 40(9):771-780.e19. PubMed ID: 22659388
[TBL] [Abstract][Full Text] [Related]
46. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Zingariello M; Martelli F; Ciaffoni F; Masiello F; Ghinassi B; D'Amore E; Massa M; Barosi G; Sancillo L; Li X; Goldberg JD; Rana RA; Migliaccio AR
Blood; 2013 Apr; 121(17):3345-63. PubMed ID: 23462118
[TBL] [Abstract][Full Text] [Related]
48. Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms.
Ha JS; Jung HR
Ann Clin Lab Sci; 2015; 45(3):308-14. PubMed ID: 26116595
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.
Hasselbalch HC; Skov V; Stauffer Larsen T; Thomassen M; Hasselbalch Riley C; Jensen MK; Bjerrum OW; Kruse TA
PLoS One; 2014; 9(1):e85567. PubMed ID: 24454890
[TBL] [Abstract][Full Text] [Related]
50. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
51. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
[TBL] [Abstract][Full Text] [Related]
52. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
53. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
Kapor S; Momčilović S; Kapor S; Mojsilović S; Radojković M; Apostolović M; Filipović B; Gotić M; Čokić V; Santibanez JF
Adv Exp Med Biol; 2023; 1408():273-290. PubMed ID: 37093433
[TBL] [Abstract][Full Text] [Related]
54. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
[TBL] [Abstract][Full Text] [Related]
55. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.
Bock O; Höftmann J; Theophile K; Hussein K; Wiese B; Schlué J; Kreipe H
Am J Pathol; 2008 Apr; 172(4):951-60. PubMed ID: 18349123
[TBL] [Abstract][Full Text] [Related]
56. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis.
Bianchi E; Ruberti S; Rontauroli S; Guglielmelli P; Salati S; Rossi C; Zini R; Tagliafico E; Vannucchi AM; Manfredini R
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098757
[TBL] [Abstract][Full Text] [Related]
57. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
58. [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations].
Shi ZX; Zhang PH; Li B; Fang LH; Xu ZF; Qin TJ; Liu JQ; Hu NB; Pan LJ; Qu SQ; Liu D; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):798-805. PubMed ID: 33190435
[No Abstract] [Full Text] [Related]
59. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.
Song J; Hussaini M; Zhang H; Shao H; Qin D; Zhang X; Ma Z; Hussnain Naqvi SM; Zhang L; Moscinski LC
Am J Clin Pathol; 2017 May; 147(5):444-452. PubMed ID: 28419183
[TBL] [Abstract][Full Text] [Related]
60. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]